Moreover, a recent report described that treatment of lung cancer with erlotinib, which is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, resulted in dramatic cell death and paradoxical enrichment of cells with CSC-like properties through EGFR-dependent Notch signal activation [39]. This evidence concerns the gene EGFR and lung cancer.